Phosphono-platelet activating factor I. Synthesis of 1-O-hexadecyl-2-O-acetyl-glyceryl-3-(2-trimethyl ammonium-methyl) phosphonate and its platelet activating potency

The total synthesis of 1-O-alkyl-2-acetyl-3-glyceryl-(2-trimethyl ammoniummethyl) phosphonate, the phosphono analogue of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine, is described. The phosphonolipid shows much lower activity than the phospholipid stimulating serotonin release from rabbit platelets.

Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils

Human polymorphonuclear leukocytes (PMN) incubated with 1-O-[3H]alkyl-2-acetyl-sn-glycero-3-phosphocholine (1-[3H]alkyl-2-acetyl-GPC; platelet activating factor) inactivated the compound by removing the acetyl group and replacing it with a long chain acyl residue. The nature of the acyl group added at the 2-position of the 1-O-[3H]alkyl-2-acyl-GPC formed was examined by argentation chromatography and by reverse phase high performance liquid chromatography. A striking selectivity for arachidonate was observed in the acylation reaction. The major labeled component of the starting material was the 1-O-hexadecyl-linked species; high performance liquid chromatography analysis revealed that 75 to 80% of this component was acylated by arachidonate. Similarly, based on argentation thin layer chromatography, approximately 80% of the total starting material was acylated by tetraenoic acyl residues. The incorporation of 1-O-[3H]alkyl-2-lyso-GPC into 1-O-alkyl-2-acyl-GPC by the PMN was compared; no difference in the acylation pattern was observed with the 2-acetyl and 2-lyso precursors. Thus, activation of the PMN does not appear to be required to elicit the selectivity for arachidonate. When labeled 1-palmitoyl-2-lyso-GPC was compared in the system under the same conditions, it was also preferentially acylated by arachidonate; thus, it is not clear at this time whether or not the selectivity for arachidonate is physiologically limited to platelet activating factor. Our findings suggest a close relationship exists between the metabolism of platelet activating factor and arachidonate in human PMN.

Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine

Human amniotic fluid and fetal urine were examined for the presence of phospholipid platelet-activating factor (PAF). PAF was detected in lipid extracts of some samples of amniotic fluid obtained from women in labor but it was undetectable in samples of amniotic fluid obtained before the onset of labor. PAF was identified by chromatographic mobility, platelet aggregation and chemical modifications. LysoPAF was also present in amniotic fluid at higher concentrations than those of PAF. Both PAF and lysoPAF were identified also in newborn and adult urine.

Biosynthesis of platelet activating factor in rabbit polymorphonuclear neutrophils

The synthesis of platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) was studied in rabbit peritoneal polymorphonuclear neutrophils. Upon stimulation with ionophore A23187 and Ca2+, these cells are able to incorporate [3H]acetate or 1-O-[3H]alkyl-2-lyso-sn-glycero-3-phosphocholine into platelet activating factor. Under the same incubation conditions, however, the cells do not synthesize platelet activating factor from [14C]hexadecanol, which is an immediate precursor of O-alkyl chains in the de novo pathway. In the absence of ionophore, [14C] hexadecanol is incorporated into 1-O-alkyl-2-acyl-sn-glycerol-3-phosphate and subsequently into the 1-O-alkyl-linked choline and ethanolamine phosphoglyceride pools. However, in the presence of ionophore, [14C] hexadecanol incorporation is limited to phosphatidic acid, perhaps due to the inhibition of choline phosphotransferase. These findings provide strong evidence that platelet activating factor is synthesized by a deacylation-reacylation mechanism. Upon stimulation, these cells can utilize both plausible substrates of this pathway to make the final product, while under the same conditions it appears that a key step of the de novo pathway is inhibited.

Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor

"Saturated" and "unsaturated" platelet-activating factor (PAF) obtained from ratfish liver oil were proved to exert potent stimulation on human blood platelets. Using 0.025 to 1.0 mumol/1 PAF a dose-dependent platelet aggregation in platelet-rich plasma was observed. During PAF-induced irreversible aggregation a 9 to 40% release of platelet bound serotonin occurred. The specific effect of PAF, however, seems to be limited to induce reversible aggregation since second wave of aggregation and serotonin release were suppressed by a combination of acetylsalicylic acid and an ADP scavenging system. Incubation of PAF for 30 min in plasma resulted in a 90% loss of its platelet aggregating power. Subthreshold concentrations of PAF enhanced the platelet aggregation triggered by suboptimal concentrations of ADP, epinephrine, or collagen. Vice versa non-aggregating concentrations of ADP, epinephrine, collagen, Ca-ionophore A 23,187, or arachidonic acid amplified PAF-induced platelet aggregation. The synergistic effect of PAF and other stimuli of blood platelet activation can be partly interpreted as a stimulating effect of PAF on the metabolization of arachidonic acid.

Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor

The proaggregatory potencies of synthetic analogs of platelet activating factor (PAF-acether: 1-0-alkyl 2-0-acetyl sn-glycero-3-phosphorylcholine) were tested in rabbit and human platelet rich plasma (PRP). For activation of human compared to rabbit platelets about 30 to 100 times higher concentrations of the compounds were needed, but the relative potencies of the analogs tested were quite similar in both species. The absolute stereospecificity required for platelet activation could be confirmed and extended also to the pair of enantiomers with a cis-9 double bond in the 0-alkyl chain and to the enantiomers with the 0-alkyl chain at C-2 of glycerol. The propionyl ester at C-2 of glycerol proved to be as potent as the acetyl ester but replacement by the formyl as well as by the butyryl ester reduced the activity to less than three per cent. Variations at the 3-phosphorylcholine substituent all abolished the activity. It appears that the correct stereochemistry and a phosphorylcholine group in a strictly defined position towards the asymmetric C-2 of the glycerol backbone are absolute requirements for activity whereas variations in the alkyl and the short chain acyl groups have not as dramatic consequences.

Lipid-mediator synthesis in peritoneal macrophages from mice injected with immunostimulants

The metabolism of bioreactive lipid mediators was studied in two types of activated macrophages (M phi). We compared the capacity of resident and activated M phi to release, upon a zymosan challenge, cyclooxygenase and lipoxygenase products as well as PAF-acether (platelet-activating factor) and its 2-lyso precursor. Activated M phi were obtained from mice injected intraperitoneally either with nonviable C74 streptococci (St-M phi) or with trehalose dimycolate, a defined immunostimulant isolated from Mycobacterium tuberculosis (TDM-M phi). Both activated populations exhibited common features: conversion of endogenous [14C]arachidonic acid into prostaglandin E2 and thromboxane A2 rather than into prostaglandin I2 and low biosynthesis of PAF-acether, probably due to an impairment of the acetylation step. However, contrary to St-M phi, TDM-M phi did not display a marked overall reduction of arachidonate metabolism. In addition, as compared to resident M phi, TDM-M phi presented a ratio of thromboxane B2/6-ketoprostaglandin F1 alpha 30-fold higher, a better conversion of leukotriene C to leukotriene D and a higher capacity to release the PAF-acether they synthesize. These macrophages thus seem to be valuable tools for studying the formation of mediators and for determining specific markers of an activated state.

Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets

32P-Labelled washed rabbit platelets were incubated with 0.6 nM platelet activating factor (PAF-acether), giving a full aggregation and release response within 30-60 s. The major phospholipid changes observed under these conditions were: (1) An increased labelling of phosphatidic acid (PA) within 10 s and of phosphatidylinositol (MPI) at 30 s, reflecting the activation of the MPI cycle via the cytosolic phospholipase C; (2) an enhancement of phosphatidylinositol-4-phosphate (DPI) and phosphatidylinositol-4,5-bisphosphate (TPI) labelling at later incubation times; (3) an early degradation of TPI with a counterbalancing formation of DPI. The latter changes suggest a receptor-mediated stimulation of TPI-phosphomonoesterase, the role of which in the mechanism of platelet activation is discussed.

Hypotensive and vasodilatory activity of (+/-) 1-o-octadecyl-2-acetyl glyceryl-3-phosphorylcholine in the normotensive rat

Synthetic (+/-) 1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine (octadecyl-AGPC) in microgram/kg doses given intravenously effectively and potently lowered mean arterial blood pressure in conscious and anesthetized normotensive rats. The hypotensive activity was much more pronounced in the anesthetized rat than in the conscious rat. The hypotension was associated with a significant elevation in plasma renin activity (PRA). In the rat in which the hindquarters were perfused, octadecyl-AGPC given intraarterially effectively decreased the perfusion and systemic pressures in a dose-dependent manner. Pharmacological blockade with specific cholinergic, histaminergic or beta-adrenergic receptor antagonists, did not block or attenuate the octadecyl-AGPC-induced reduction in perfusion or systemic pressure. These results suggest that the hypotensive activity of octadecyl-AGPC in the normotensive rat is the result of direct vasodilation and not the result of cholinergic, histaminergic or beta-adrenergic receptor interaction.

Effect of structural analogues of PAF-acether on platelet desensitization

The 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (PAF-acether) aggregates rabbit platelets and desensitizes them to a second challenge with the same agonist but not to arachidonic acid. The desensitizing activities of 14 analogues of PAF-acether were explored with particular attention to the dose-response dependency of the desensitization process. PAF-acether was 500-fold more active than its 1-O-acyl analogues. The 2-lyso PAF-acether was inactive and the PAF-acether enantiomer 2000 times less effective than the natural isomer, thus confirming the importance of the presence and steric position of the 2-acetate group. The desensitizing activities of the 2-propionyl and the 2-butyryl analogues were close to that of PAF-acether. Substituting an ether to an ester bond at the 2-position indicated that the number of carbon of the 2-substituant seems more determinant than the nature of the linkage for the desensitizing process. Indeed, the 2-ethoxy and the 2-methoxy analogues were 87 and 5000 times less active than PAF-acether respectively. The presence of methyl groups on the nitrogen base is also critical to desensitize platelets. The desensitizing potency of the tested phospholipids was always identical to their aggregating efficiency. It is suggested that these compounds activate cells through a common mechanism.

Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite

3H-PAF-acether (Alkyl-[1', 2'-3H]- 2-acetyl-sn-glyceryl-3-phosphorylcholine) was time-dependently transformed by plasma-free rabbit platelets into an unknown product, "PX", which was distinct from lyso-PAF-acether. This effect was specific for platelets since plasma only converted 3H-PAF-acether into lyso-3H-PAF-acether and platelets were not effective in metabolizing lyso-3H-PAF-acether. Platelet aggregation did not interfere with the formation of "PX". The latter is a novel platelet metabolite of PAF-acether with as yet unknown biological properties.

Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats

Fourteen 23 week old male spontaneously hypertensive rats (SHR) were randomly divided into saline control or phospholipid (I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) treatment groups. Four weeks of baseline systolic blood pressure (SBP) and heart rate (HR) measurements were determined via tail plethysmography. On week 25 of the baseline period a 1.5 ml blood sample was taken by tail clip for analysis of norepinephrine (NE), epinephrine (E), and plasma renin activity (PRA). On the following week, a single injection of phospholipid (11 ug/kg, s.c.) was given to the experimental animals following baseline SBP and HR determinations. A similar procedure was employed for control subjects, except they received an injection of normal saline (0.5 ml, s.c.). Systolic BP and HR responses were monitored for 24 minutes following the injection. A 1.5 ml blood sample was taken at the end of the 4th minute for NE, E, and PRA assays. A significant drop in SBP (202 +/- 5 mmHg to 124 +/- 6 mmHg) and an increase in HR (431 +/- 17 bpm to 519 +/- 21 bpm) were observed for experimental animals, but not for control subjects. Plasma NE increased significantly (446 +/- 42 pg/ml to 1099 +/- 77 pg/ml), but E remained unchanged following treatment with the phospholipid. Plasma renin activity increased for both groups, but this change was only significant for the experimental group (18.1 +/- 5.7 ng Al/ml/hr to 34.3 +/- 3.6 ng Al/ml/hr). Thus, it appears that I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine is a potent antihypertensive vasodilating agent which stimulates baroreceptor mediated sympathetic discharge to the heart and kidneys of the SHR.

Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. Phospholipase A2 and acetyltransferase activities during phagocytosis and ionophore stimulation

1-Alkyl-2-acyl-sn-glycero-3-phosphocholine (alkyl-acyl-GPC) comprises 11% of the total phospholipids of rat alveolar macrophages. This endogenous pool of alkylacyl-GPC was prelabeled by incubating the macrophages with [1,2-3H]alkyllyso-GPC (54 Ci/mmol), which enters the cells and is acylated. The effect of various stimuli on the synthesis and release into the media of labeled alkylacetyl-GPC (platelet-activating factor) from the cells was used to establish the role of inactive alkylacyl-GPC as a precursor of the biologically active derivative. A phagocytic agent (zymosan, 100 micrograms/ml) and an ionophore (A23187, 2 microM) stimulated the release of both alkylacetyl-GPC and alkyllyso-GPC into the media at the expense of cellular alkylacyl-GPC. Phospholipase A2 activity (at pH 4.5 and in 1 mM EDTA) was also increased in the media. The stimulatory effect of zymosan and the ionophore on alkylacetyl-GPC release was prevented by mepacrine (0.1 mM), an agent that inhibits the release of fatty acids from phospholipids. These data indicate that phospholipase activity is required for the biosynthesis of alkylacetyl-GPC. However, since the inhibitory effect of mepacrine was not apparent when acetate was present, it appears that the acetylation step is rate limiting. Exposure of alveolar macrophages in culture to zymosan or A23187 stimulated acetyltransferase activity 250-300%. In contrast, phorbol myristate acetate (1.6 microM), which stimulated the accumulation of lysophospholipids but not the level of alkylacetyl-GPC in the media, did not substantially increase acetyltransferase activity. We conclude that alkylacyl-GPC serves as a precursor of alkylacetyl-GPC and that the production of this potent mediator by rat alveolar macrophages can be stimulated by agents that affect phospholipase A2 and acetyltransferase activities. The latter enzyme appears to have a regulatory function in the biosynthesis of alkylacetyl-GPC.

alpha-Adrenergic blocking action of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats

The effect of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine (HAGPC), a major component of antihypertensive polar renomedullary lipid, on the pressor responses to norepinephrine and angiotensin II was investigated in normal Wistar rats. The pressor activity of norepinephrine (1 microgram/kg of body weight (BW)) and angiotensin II (40 ng/kg BW) were markedly suppressed when these substances were injected immediately after intravenous administration of 80 nmol/kg BW of HAGPC. When HAGPC was infused continuously at a rate of 20 nmol/kg BW/min, pressor responses to bolus injection of graded doses (0.5 to 10 micrograms/kg BW) of norepinephrine were significantly lowered, but pressor responses to 10 to 200 ng/kg BW of angiotensin II were not affected. These observations suggest that HAGPC has alpha-adrenergic blocking activity and does not influence angiotensin II receptors.

Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types

The release and formation of PAF-acether and of its deacetylated precursor (2-lyso PAF-acether) have been determined on mouse macrophages (M phi), human polymorphonuclear neutrophils (PMN) and rabbit platelets using specific secretagogue stimuli in the same experimental conditions. It was found that as opposed to M phi, PMN and platelets were good releasers of PAF-acether. However, the total amount of PAF-acether formed by M phi and PMN was larger than that formed by platelets. The total amount of 2-lyso PAF-acether varied also for the three cell types, with platelets being by far the best producer. Calculation of the amount of PAF-acether formed from 2-lyso PAF-acether indicated that M phi and PMN possess a higher acetylating ability than platelets.

Platelet-activating factor (PAF-acether), an activator of neutrophil functions

The effect of totally synthetic PAF-acether (1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine), 2-lyso PAF-acether (1-O-octadecyl-sn-glyceryl-3-phosphorylcholine) and lyso-phosphatidylcholine on enzyme release and superoxide production from human polymorphonuclear neutrophils (PMN were studied. PMN (2 X 10(6) ml-1) were incubated at 37 degrees C with various concentrations of phospholipids in the absence of cytochalasin B. At 10(-7) M, PAF-acether induced superoxide production and beta-glucuronidase, acid phosphatase and lysosyme release, but not that of cytoplasmic lactic dehydrogenase. In the same condition 2-lyso PAF-acether and lyso-phosphatidylcholine were ineffective. In the presence of phagocytic stimuli PAF-acether enhanced in the range from 10(-7) M to 10(-10) M the enzyme release and only at 10(-7) M the superoxide production. Thus, the capacity of PAF-acether to stimulate PMN, as well as platelet function, indicates a prominent role for this lipid mediator in inflammatory processes.

Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release

Synthetic 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (PAF) and 1-O-alkyl-sn-glyceryl-3-phosphorylcholine (lyso-PAF) have previously been shown to induce chemotaxis and chemokinesis of human neutrophils. We present here data showing that these agents are inactive by themselves, but that they enhance neutrophil secretion once it has been initiated by a calcium ionophore or by zymosan. Two substances, the lipid eosinophil chemotactic factor (ECF) and the lysosomal enzyme beta-glucuronidase, are used as markers for neutrophil release. PAF augments secretion of both substances in a dose-dependent fashion, with lyso-PAF being less potent. The kinetics of enhancement are very rapid (less than 2 min) and are not reversible by washing of the cells. A pyrazoline derivative that inhibits arachidonate cyclo-oxygenation and lipoxygenation, reduces the enhancing effect of PAF and lyso-PAF. PAF, and less so lyso-PAF, are thus potentially important modulators of neutrophil secretion during inflammatory processes.

Ether phospholipids in guinea pig polymorphonuclear leukocytes and macrophages. Occurrence of high levels of 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine

Significant proportions of the choline phosphoglycerides (CPG) were found to contain alkyl either-type moieties (e.g., 1-O-alkyl-2-acyl-glycero-3-phosphocholine) in both guinea pig peritoneal exudate polymorphonuclear leukocytes (16.4%) and macrophages (13.5%). High proportions of the ethanolamine phosphoglycerides (EPG) contained alkenyl either moieties in both cells (37.2 and 41.2%), while the proportions of the CPG containing alkenyl moieties and of the EPG containing alkyl moieties were shown to be small. The either phospholipid composition as well as the fatty chain profiles of these two types of cells had relatively similar patterns. However, the fatty chains at the 1- and 2-positions for alkenyl either, alkyl ether and diacyl phosphoglycerides showed considerable differences. The amount of 16:0 at the 1-position was higher in alkyl compounds than that in diacyl compounds of the CPG. This was also the case in either-containing and diacyl EPG. The most predominant fatty acids at the 2-position was 18:2, in each lipid class, except for the alkenyl CPG. The amounts of 20:4 and other polyunsaturated fatty acids were low in every lipid class, though ether compounds contained higher amounts of 20:4 than diacyl compounds, particularly for EPG.

Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism

Since rat platelets fully responsive to thrombin and collagen did not respond by releasing 3H-serotonin with up to 10 micrograms/ml of synthetic PAF-acether, the rat, contrariwise to the rabbit, was considered to be an appropriate model to study the actions of PAF-acether not mediated through the activation of platelets and the subsequent release of their inflammatory mediators. We developed an experimental approach using 57Co and 113Sn radiolabeled microspheres to assess the effect of PAF-acether on cardiac output, peripheral vascular resistance, and regional flows and resistance. The effect on vascular permeability and blood volume was studied by measuring the clearance of 125I-HSA and the variations of the hematocrit. A significant fall in blood pressure and peripheral vascular resistance was found with doses of PAF-acether ranging from 0.05 to 5 micrograms. Moreover, the higher doses of PAF-acether also induced a marked depletion of blood volume. A significant fall in spleen, coronary, and kidney output, but not in cardiac output, was also found. Our data show that PAF-acether, by itself, induces a drop in peripheral vascular resistance and, at higher doses, also in circulating volume, accounting for both by the hypotensive effect. The redistribution of cardiac output seems to be the expression of a nonuniform action of the compound on the vascular resistance of the different organs.

Effect of synthetic PAF-acether on human neutrophil function

Synthetic PAF-acether was studied for its effect on human neutrophil migration and secretion. Based on checkerboard analysis, the factor is chemokinetic for neutrophils, but it also enhances ECF-stimulated chemotaxis. By itself, PAF-acether does not induce ECF or beta-glucuronidase secretion from neutrophils, but it causes a dose-dependent enhancement of release in the presence of zymosan. PAF-acether thus potentially modulates neutrophil functions during inflammatory events.

New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixtures

A new method of synthesis of octadecyl platelet-activating factor (PAF; 1-O-octadecyl 2-O-acetyl sn-glycero-3-phosphorylcholine) is described. Its advantage is to proceed by way of the 'lyso-PAF' which may be substituted by various groups, while avoiding the inconveniences of the total synthesis already described. Moreover, the intermediates in synthesis are easier to purify, with better yields. The platelet-aggregating activity of synthetic PAF, is enantiomer (3-O-octadecyl) and racemic mixtures were 2.7 . 10(-10), 1.7 . 10(-7) and 2.2 . 10(-10) M, respectively. These results indicate the stereospecificity of platelet activation induced by PAF.

Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids

Evidence is presented for the simultaneous release of platelet-activating factor (PAF-acether) and of its deacetylated derivative (lyso-PAF-acether) from hog leukocytes. On the basis of spectroscopy and chemical reactions, the structure of O-deacetyl-PAF is shown to be 1-O-alkylglyceryl 3-phosphorylcholine, an alkyl ether analog of lyso-phosphatidylcholine. Acetylation of lyso-PAF yields a compound with biological activity and chromatographical behavior indistinguishable from those of native PAF. Lyso-PAF may be considered to be either the precursor or the enzymatic degradation product of PAF. The usefulness of chemical ionization mass spectrometry for structural determination of phospholipids is also demonstrated.